-+ 0.00%
-+ 0.00%
-+ 0.00%

Baili Tianheng announced that the company's self-developed phase III randomized controlled clinical trial for her2-expressed platinum-resistant platinum-resistant ovarian cancer, fallopian tube cancer, and primary peritoneal cancer was recently completed.

Zhitongcaijing·09/29/2026 10:57:08
Listen to the news
Baili Tianheng announced that the company's self-developed phase III randomized controlled clinical trial for her2-expressed platinum-resistant platinum-resistant ovarian cancer, fallopian tube cancer, and primary peritoneal cancer was recently completed.